Identification of the Key Genes and Characterizations of Tumor Immune Microenvironment in Lung Adenocarcinoma (LUAD) and Lung Squamous Cell Carcinoma (LUSC)

Overview

Journal J Cancer

Specialty Oncology

Date 2020 Aug 4

PMID 32742444

Citations 24

Authors

Lemeng Zhang

Jianhua Chen

Tianli Cheng

Hua Yang

Haitao Li

Changqie Pan

Affiliations

Soon will be listed here.

Abstract

This study aimed to investigate the key genes and immune microenvironment involved in different TNM stages of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). The gene expression and clinical characteristics data were downloaded from the genomic data commons (GDC) database. After initial data processing, the characteristics of the immune microenvironment were analyzed. The differentially expressed genes (DEGs) in tumor vs. normal, and in early vs. advanced stages were screened, followed by Spearman correlation test for tumor infiltrating immune cells (TIICs) to identify immune-related genes. Finally, functional enrichment, protein-protein interaction, and survival analyses were performed. In LUAD, early stage was with higher immune scores, greater number of memory B cells and M0 macrophages compared to advanced stage. M0 and M2 macrophages, and resting memory CD4+ T cells accounted for a large proportion of TIICs in LUAD. The abundance of M0 macrophage infiltration was significantly correlated with the TNM stage and survival. In LUSC, early stage was with higher cytolytic activity and neoantigen burden compared to advanced stage. M0 and M2 macrophages, and plasma cells accounted for a large proportion of TIICs in LUSC. The abundance of resting and activated mast cells was significantly correlated with TNM stage, while resting dendritic cells, eosinophils, activated memory CD4 T cells, and mast cells were significantly correlated with prognosis. Tumor mutation burden analysis revealed that the median of variants per sample decreased from stage I to IV in LUAD, while it increased in LUSC. Further, 83 and 9 immune-related DEGs were identified in LUAD and LUSC, respectively, of which 23 genes in LUAD and 2 genes in LUSC correlated with survival. In conclusion, we identified the key genes, and characterized the tumor immune microenvironment in LUAD and LUSC which may provide therapeutic targets for the treatment of NSCLC.

Citing Articles

Functional exploration and drug prediction on programmed cell death-related biomarkers in lung adenocarcinoma.

Zhang X, Liu T, Hao Y, Guo H, Li B Heliyon. 2024; 10(17):e36616.

PMID: 39281570 PMC: 11401088. DOI: 10.1016/j.heliyon.2024.e36616.

Significance of as a biomarker for clinical prognosis, immune infiltration, and drug therapy in lung squamous cell carcinoma.

Lin H, Wang J, Shi Q, Wu M PeerJ. 2024; 12:e17338.

PMID: 38708353 PMC: 11069361. DOI: 10.7717/peerj.17338.

Long noncoding RNA LINC00921 serves as a predictive biomarker for lung adenocarcinoma: An observational study.

Xu H, Xiong W, Liu X, Wang Y, Shi M, Shi Y Medicine (Baltimore). 2024; 103(7):e37179.

PMID: 38363898 PMC: 10869092. DOI: 10.1097/MD.0000000000037179.

Integrating DNA methylation and gene expression data in a single gene network using the iNETgrate package.

Sajedi S, Ebrahimi G, Roudi R, Mehta I, Heshmat A, Samimi H Sci Rep. 2023; 13(1):21721.

PMID: 38066050 PMC: 10709411. DOI: 10.1038/s41598-023-48237-8.

Intratumoral Microbiota-Host Interactions Shape the Variability of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma in Recurrence and Metastasis.

Zhou X, Ji L, Ma Y, Tian G, Lv K, Yang J Microbiol Spectr. 2023; 11(3):e0373822.

PMID: 37074188 PMC: 10269859. DOI: 10.1128/spectrum.03738-22.

References

Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T . Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008; 113(6):1387-95. DOI: 10.1002/cncr.23712. View

Clancy T, Dannenfelser R, Troyanskaya O, Malmberg K, Hovig E, Kristensen V . Bioinformatics Approaches to Profile the Tumor Microenvironment for Immunotherapeutic Discovery. Curr Pharm Des. 2017; 23(32):4716-4725. DOI: 10.2174/1381612823666170710154936. View

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

Rooney M, Shukla S, Wu C, Getz G, Hacohen N . Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61. PMC: 4856474. DOI: 10.1016/j.cell.2014.12.033. View

Chalmers Z, Connelly C, Fabrizio D, Gay L, Ali S, Ennis R . Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017; 9(1):34. PMC: 5395719. DOI: 10.1186/s13073-017-0424-2. View

Zhou C, Zhu C, Liu Q . Toward in silico Identification of Tumor Neoantigens in Immunotherapy. Trends Mol Med. 2019; 25(11):980-992. DOI: 10.1016/j.molmed.2019.08.001. View

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

Milling S . Adipokines and the control of mast cell functions: from obesity to inflammation?. Immunology. 2019; 158(1):1-2. PMC: 6700462. DOI: 10.1111/imm.13104. View

Roufas C, Chasiotis D, Makris A, Efstathiades C, Dimopoulos C, Zaravinos A . The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis. Front Oncol. 2018; 8:27. PMC: 5826382. DOI: 10.3389/fonc.2018.00027. View

10.

Yao D, Gu P, Wang Y, Luo W, Chi H, Ge J . Inhibiting polo-like kinase 1 enhances radiosensitization via modulating DNA repair proteins in non-small-cell lung cancer. Biochem Cell Biol. 2017; 96(3):317-325. DOI: 10.1139/bcb-2017-0063. View

11.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

12.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

13.

Beadsmoore C, Screaton N . Classification, staging and prognosis of lung cancer. Eur J Radiol. 2002; 45(1):8-17. DOI: 10.1016/s0720-048x(02)00287-5. View

14.

Goc J, Germain C, Vo-Bourgais T, Lupo A, Klein C, Knockaert S . Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 2013; 74(3):705-15. DOI: 10.1158/0008-5472.CAN-13-1342. View

15.

Devarakonda S, Rotolo F, Tsao M, Lanc I, Brambilla E, Masood A . Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. J Clin Oncol. 2018; 36(30):2995-3006. PMC: 6804865. DOI: 10.1200/JCO.2018.78.1963. View

16.

Sekimoto N, Suzuki Y, Sugano S . Decreased KPNB1 Expression is Induced by PLK1 Inhibition and Leads to Apoptosis in Lung Adenocarcinoma. J Cancer. 2017; 8(19):4125-4140. PMC: 5706017. DOI: 10.7150/jca.21802. View

17.

Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View

18.

Chen H, Chong W, Teng C, Yao Y, Wang X, Li X . The immune response-related mutational signatures and driver genes in non-small-cell lung cancer. Cancer Sci. 2019; 110(8):2348-2356. PMC: 6676111. DOI: 10.1111/cas.14113. View

19.

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y . Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5):453-7. PMC: 4739640. DOI: 10.1038/nmeth.3337. View

20.

Wang X, Kong C, Xu W, Yang S, Shi D, Zhang J . Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature. Thorac Cancer. 2019; 10(10):1904-1912. PMC: 6775017. DOI: 10.1111/1759-7714.13163. View